LGBTQ-Affirmative Therapy for Mental Health Issues
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the efficacy of an LGBTQ-affirmative individual cognitive behavioral psychotherapy (CBT) and LGBTQ-affirmative family therapy (attachment-based family therapy for sexual and gender minority young adults; ABFT-SGM) delivered via telehealth to a sample of sexual and gender minority adults with nonaccepting parent(s) in New York, Pennsylvania, Connecticut, and Israel. The investigators will assess whether both treatments are associated with significant decreases in depressive and anxiety symptoms. The investigators will also assess whether and how each treatment achieves reductions in mental health symptoms through specific mechanisms (e.g., rejection sensitivity, internalized stigma, emotion dysregulation, parental rejection and acceptance).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you have started a new medication in the past 30 days.
What data supports the effectiveness of the treatment ABFT-SGM for mental health issues in LGBTQ+ young adults?
Research shows that Attachment-Based Family Therapy (ABFT) has been adapted for LGBTQ+ youth and has shown promise in reducing suicidal thoughts and improving family communication. Additionally, cognitive behavioral therapy (CBT) tailored for sexual and gender minority youth has been effective in improving mood and coping skills.12345
Is LGBTQ-Affirmative Therapy safe for humans?
Research on LGBTQ-Affirmative Therapy, including Attachment-Based Family Therapy (ABFT) and cognitive behavioral therapy (CBT) adapted for sexual and gender minority youth, suggests it is generally safe. Studies show that these therapies are feasible and acceptable, with participants completing treatment and reporting positive experiences.12345
How does the treatment ABFT-SGM differ from other treatments for mental health issues in LGBTQ+ youth?
ABFT-SGM is unique because it combines attachment-based family therapy with LGBTQ-affirmative cognitive behavioral therapy, specifically tailored to address the unique challenges faced by sexual and gender minority youth, such as family rejection and societal exclusion, which are not typically addressed in standard treatments.12356
Research Team
John E Pachankis, PhD
Principal Investigator
Yale University
Gary M Diamond, PhD
Principal Investigator
Ben-Gurion University of the Negev
Eligibility Criteria
This trial is for sexual and gender minority adults over 20 in New York or Connecticut with nonaccepting parents willing to join therapy. Participants must have elevated depression or anxiety, not be on new meds within the last month, and can't be under legal treatment mandates or exhibit active suicidality/homicidality, psychosis, mania, or severe cognitive impairment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 16 weekly sessions of either LGBTQ-affirmative CBT or ABFT-SGM delivered via telehealth
Follow-up
Participants are monitored for changes in mental health symptoms and psychosocial mechanisms
Treatment Details
Interventions
- ABFT-SGM
- LGBTQ-affirmative CBT
ABFT-SGM is already approved in United States for the following indications:
- Depressive symptoms in sexual and gender minority adults
- Anxiety symptoms in sexual and gender minority adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Ben-Gurion University of the Negev
Collaborator
Israel Science Foundation
Collaborator